RSV Vaccine Studies

For Infants and Children Ages 6-Months to 5-Years-Old. Compensation is provided to study participants.

RSV (Respiratory Syncytial Virus) is a common seasonal virus. Infants and children are at greater risk of acquiring RSV because of their maturing immune system and lack of prior exposure. Most of the time it causes a mild illness like a cold, but for some children RSV leads to a more severe lung problem.

Unfortunately, 2-3 infants out of every 100 with RSV infections become hospitalized.  In fact, each year in the United States an estimated 58,000 – 80,000 children younger than 5 are hospitalized due to RSV infection.

Compensation of $720 - $1,040 is available for study participants.

Please complete the form below if you would like to learn more from our team about participating, or give us a call at (615) 329-2222 with any questions.

Help Research an RSV Vaccine That Protects Infants and Children

Please share your name and contact information so that we can speak with you about the study, answer any questions, and plan an initial visit.

This field is for validation purposes and should be left unchanged.
Your Name(Required)
How would you describe yourself?*
*Please check all that apply.

Read About the Study Here

The purpose of this global study is to further evaluate the safety and effectiveness of a research RSV vaccine compared to a placebo. The study will last approximately 24 months.

Currently there are two FDA approved vaccines for RSV, both for adults 60 and older. There is no approved vaccine for infants and children.